Note 11 - Business Combinations, Dispositions and Other Strategic Investments (Details) - Consideration Paid for the Merck Acquisition and the Fair Value of the Acquired Assets and Assume Liabilities (Merck Acquisition [Member], USD $) In Millions, unless otherwise specified	0 Months Ended	3 Months Ended
	Nov. 15, 2013	Dec. 31, 2013
Note 11 - Business Combinations, Dispositions and Other Strategic Investments (Details) - Consideration Paid for the Merck Acquisition and the Fair Value of the Acquired Assets and Assume Liabilities [Line Items]
Product rights		$ 55.7
Prepaid expenses		0.1
Deferred tax assets, net		0.7
Total fair value of acquired assets		56.5
Consideration paid	52.8	52.8
Gain from bargain purchase		3.7
AzaSite [Member]
Note 11 - Business Combinations, Dispositions and Other Strategic Investments (Details) - Consideration Paid for the Merck Acquisition and the Fair Value of the Acquired Assets and Assume Liabilities [Line Items]
Product rights		13.8
Cosopt [Member]
Note 11 - Business Combinations, Dispositions and Other Strategic Investments (Details) - Consideration Paid for the Merck Acquisition and the Fair Value of the Acquired Assets and Assume Liabilities [Line Items]
Product rights		21.6
Cosopt PF [Member]
Note 11 - Business Combinations, Dispositions and Other Strategic Investments (Details) - Consideration Paid for the Merck Acquisition and the Fair Value of the Acquired Assets and Assume Liabilities [Line Items]
Product rights		$ 20.3